Claims for Patent: 5,011,678

Summary for Patent: 5,011,678

Title:	Composition and method for administration of pharmaceutically active substances
Abstract:	Pharmaceutically active substances are administered in aerosol form by applying to a mucosal surface of the body a composition comprising a medically effective amount of a pharmaceutically active substance, a biocompatible amphiphilac steroid and a bicompatible (hydro/fluoro)carbon propellant.
Inventor(s):	Wang; Yu-chang J. (Los Altos, CA), Lee; William A. (Los Altos, CA), Narog; Blair (Palo Alto, CA)
Assignee:	California Biotechnology Inc. (Mountain View, CA)
Application Number:	07/305,520
Patent Claims:	1. A nonaqueous, dry powder composition for the transmucosal administration of pharmaceutically active substance, comprising a particulate suspension of: (a) a medically effective amount of a polypeptide drug and (b) a biocompatible steroid of the formula ##STR2## wherein a dashed line represents a single or double bond; D represents a group having a molecular weight below 600 daltons which renders an effective amount of said steroid water soluble within the range of about pH 2 to about pH 12; E represents OAc, OH, a lower alkyl group or a lower heteroalkyl group; G represents OAc, OH, a lower alkyl group or a lower heteroalkyl group; W represents OAc or H; and Q, V, and X, each individually, represent OH or H, said steroid (i) containing two to three polar functions, exclusive of the function represented by D; and (ii) being capable of increasing the permeation of a human or animal mucosal surface by a pharmaceutically active substance, in an amount effective to increase the permeability of said body surface to a pharmaceutically active substance; and wherein said particulate suspension is suspended in a biocompatible (hydro/fluoro) carbon propellant. 2. A composition as claimed in claim 1, wherein the steroid has the formula: ##STR3## wherein a dashed line represents a single or double bond; D represents a group having a molecular weight below 600 daltons which renders an effect amount of said steroid water-soluble within the range of about pH 2 to about pH 12: E represents .beta.-OAc, .alpha.-OH, a lower alkyl group in the .beta.-position or a lower heteroalkyl group in the .alpha.- or .beta.-position; G represents .beta.-OAc, .beta.-OH, or a lower heteroalkyl group in the .alpha.-position; W represents .alpha.-OAc or H; Q represents H or OH; V represents H or .alpha.-OH; and X represents H or .alpha.-OH, said steroid containing from two to three OH groups. 3. A composition as claimed in claim 1 wherein the biocompatible (hydro/fluoro)carbon propellant comprises at least one fluorocarbon compound of the formula C.sub.n H.sub.x Cl.sub.y F.sub.z in which n is an integer from 1 to 4; x, y and z are integers such that the sum x+y+Z equals 2n+2, the sum of y+z is at least 2 and z is greater than zero. 4. A composition as claimed in claim 3, wherein n is 1 or 2. 5. A composition as claimed in claim 3 wherein the biocompatible fluorocarbon propellant comprises at least one compound selected from CCl.sub.3 F and CCl.sub.2 F.sub.2. 6. A composition as claimed in claim 1 wherein the biocompatible, amphiphilic steroid is sodium tauro-24,25-dihydrofusidate. 7. A composition as claimed in claim 1 wherein the pharmaceutically active substance is a polypeptide compound. 8. A composition as claimed in claim 7 wherein the polypeptide is selected from insulin, human growth hormone, luteinizing hormone releasing hormone, human or animal calcitonins, erythropoietin, and parathyroid hormone. 9. A composition as claimed in claim 7 wherein the polypeptide is insulin. 10. A composition as claimed in claim 1 in which the biocompatible, amphiphilic steroid and the pharmaceutically active substance are suspended in liquid (hydro/fluoro)carbon propellant in the form of particles in which they are intimately interspersed with each other. 11. A composition as claimed in claim 10 wherein the particles have a particle size from about 2 microns to about 45 microns. 12. A method of administering a particulate suspension of a pharmaceutically active substance which is substantially free of water, comprising applying to a mucosal body surface a particulate composition comprising: (a) a medically effective amount of a pharmaceutically active substance; and (b) a biocompatible steroid of the formula ##STR4## wherein a dashed line represents a single or double bond; D represents a group having a molecular weight below 600 daltons which renders an effective amount of said steroid water soluble within the range of about pH 2 to about pH 12; E represents OAc, OH, a lower alkyl group or a lower heteroalkyl group; G represents OAc, OH, a lower alkyl group or a lower heteroalkyl group; W represents OAc or H; and Q, V, and X individually, represent OH or H, said steroid (i) containing two to three polar functions, exclusive of the function represented by D; and (ii) being capable of increasing the permeation of a human or animal mucosal surface by a pharmaceutically active substance, in a amount effective to increase the permeability of said body surface to a pharmaceutically active substance, wherein said composition is delivered to the body surface by means of a biocompatible (hydro/fluoro) carbon aerosol propellant. 13. A method as claimed in claim 12, wherein the biocompatible steroid has the formula: ##STR5## wherein a dashed line represents a single or double bond; D represents a group having a molecular weight below 600 daltons which renders an effect amount of said steroid water-soluble within the range of about pH 2 to about pH 12: E represents .beta.-OAc, .alpha.-OH, a lower alkyl group in the .beta.-position or a lower heteroalkyl group in the .alpha.- or .beta.-position; G represents .alpha.-OAc, .alpha.-OH, or a lower heteroalkyl group in the .alpha.-position; W represents .alpha.-OAc or H; V represents H or .alpha.-OH; and X represents H or .alpha.-OH, said steroid containing from two to three OH groups. 14. A method as claimed in claim 12, wherein the biocompatible (hydro/fluoro)carbon propellant comprises at least one fluorocarbon compound of the formula C.sub.n H.sub.x Cl.sub.y F.sub.z in which n is an integer from 1 to 4; x, y and z are integers such that the sum of x+y+z equals 2n+2, the sum of y+z is at )east 2 and z is greater than zero. 15. A method as claimed in claim 14 wherein n is 1 or 2. 16. A method as claimed in claim 14, wherein the biocompatible fluorocarbon propellant comprises at least one fluorocarbon compound selected from CCl.sub.3 F and CCl.sub.2 F.sub.2. 17. A method as claimed in claim 12, wherein the biocompatible, amphiphilic steroid is sodium tauro-24,25 dihydrofusidate. 18. A method as claimed in claim 12, wherein the pharmaceutically active substance is a polypeptide compound. 19. A method as claimed in claim 18, wherein insulin is applied in an amount effective for the treatment of diabetes. 20. A method as claimed in claim 18, wherein human growth hormone is applied in an amount effective for the treatment of pituitary dwarfism. 21. A method as claimed in claim 18, wherein a human or animal calcitonin is applied in an amount effective for the treatment of Paget's disease or osteoporosis. 22. A method as claimed in claim 18, wherein erythropoietin is applied in an amount effective for the treatment of anemia. 23. A method as claimed in claim 12, wherein the biocompatible, amphiphilic steroid and the pharmaceutically active substance are in the form or particles in which they are intimately interspersed with each other, which are propelled into contact with the mucosal surface by the gas pressure of the biocompatible fluorocarbon propellant. 24. A method as claimed in claim 23, wherein the particles have a particle size from 2 microns to about 45 microns. 25. A method as claimed in claim 18, wherein the composition is applied intranasally. 26. A method as claimed in claim 18, wherein the composition is applied to the mucosal surfaces of the bronchopulmonary system. 27. A method of preparing a composition for the administration of a pharmaceutically active substance comprising: (a) preparing an aqueous solution containing (i) a biocompatible, amphiphilic steroid of the formula: ##STR6## wherein a dashed line represents a single or a double bond; D represents a group having a molecular weight below 600 daltons which renders an effective amount of said steroid water soluble within the range of about pH 2 to about pH 12; E represents OAc, OH, a lower alkyl group or a lower heteroalkyl group; G represents OAc, OH, a lower alkyl group or a lower heteroalkyl group; W represents oAc or H; and Q, V and X, each individually, represent OH or H, said steroid (i) containing two to three polar functions, exclusive of the function represented by D; and (ii) being capable of increasing the permeation of a human or animal mucosal surface by a pharmaceutically active substance in an amount effective to increase the permeability of said body surface to a pharmaceutically active substance; and (ii) a medically effective amount of a pharmaceutically active substance; (b) removing the water from the solution by lyophilization; (c) sizing the lyophilized composition to a particle size from about 2 microns to about 45 microns; and (d) adding the lyophilized particulate to a normally-gaseous (hydro/fluoro)carbon propellant under sufficient pressure that the propellant is in liquid form. 28. A method as claimed in claim 27, wherein the biocompatible steroid has the formula: ##STR7## wherein a dashed line represents a single or double bond; D represents a group having a molecular weight below 600 daltons which renders an effect amount of said steroid water-soluble within the range of about pH 2 to about pH 12: E represents .beta.-OAc, .beta.-OH, a lower alkyl group in the .beta.-position or a lower heteroalkyl group in the .alpha.- or .beta.-position; position; G represents .alpha.-OAc, .alpha.-OH, or a lower heteroalkyl group in the .alpha.-position; W represents .alpha.-OAc or H; Q represents H or OH; V represents H or .alpha.-OH; and X represents H or .alpha.-OH, said steroid containing from two to three OH groups. 29. A method as claimed in claim 28, wherein the biocompatible (hydro/fluoro)carbon propellant comprises at least one fluorocarbon compound of the formula C.sub.n H.sub.x Cl.sub.y F.sub.z in which n is an integer from 1 to 4; x, y and z are integers such that the sum of x+y+z equals 2n+2, the sum of y+z is at least 2 and z is greater then zero. 30. A method as claimed in claim 29, wherein n is 1 to 2. 31. A method as claimed in claim 29, wherein the biocompatible fluorocarbon propellant comprises at least one compound selected from CCl.sub.3 F and CCl.sub.2 F.sub.2. 32. A method as c)aimed in claim 27, wherein the biocompatible, amphiphilic steroid is sodium-24,25-dihydrofusidate. 33. A method as claimed in claim 27, wherein the pharmaceutically active substance is a polypeptide compound. 34. A method as claimed in claim 33, wherein the polypeptide is insulin and the aqueous solution is prepared at elevated temperature to enhance dissolution. 35. A method as claimed in claim 33, wherein a buffer is added to the aqueous solution to maintain physiologic pH. 36. A composition for the administration of a pharmaceutically active a polypeptide drug, the composition comprising a lyophilized powder formulation of: (a) a medically effective amount of the polypeptide drug and (b) a biocompatible steroid of the formula ##STR8## wherein a dashed line represents a single or double bond; D represents a group having a molecular weight below 600 daltons which renders an effective amount of said steroid water-soluble within the range of about pH 2 to about pH 12; E represents OAc, OH, a lower alkyl group or a lower heteroalkyl group; G represents OAc, OH, a lower alkyl group or a lower heteroalkyl group; W represents OAc or H; and Q, V and X, each individually, represent OH or H, said steroid (i) containing two to three polar functions, exclusive of the function represented by D; and (ii) being capable of increasing the permeation of a human or animal mucosal surface by a pharmaceutically active substance, in an amount effective to increase the permeability of said body surface to a pharmaceutically active substance; and wherein said particulate suspension is suspended in a biocompatible (hydro/fluoro) carbon propellant. 37. A composition as claimed in claim 36 wherein the biocompatible (hydro/fluoro) carbon propellant comprises at least one fluorocarbon compound of the formula C.sub.n H.sub.x Cl.sub.y F.sub.z in which n is an integer from 1 to 4; x, y and z are integers such that the sum x+y+z equals 2n+2, the sum of y+z is at least 2 and z is greater than zero. 38. A composition as claimed in claim 37 wherein n is 1 or 2. 39. A composition as claimed in claim 37 wherein the biocompatible fluorocarbon propellant comprises at least one compound selected from CCl.sub.3 F and CCl.sub.2 F.sub.2. 40. A composition as claimed in claim 36 wherein the biocompatible, amphiphilic steroid is sodium tauro-24,25-dihydrofusidate. 41. A composition as claimed in claim 36 wherein the polypeptide drug is selected from insulin, human growth hormone, luteinizing hormone releasing hormone, human or animal calcitonins, erythropoietin, and parathyroid hormone. 42. A composition as claimed in claim 41 wherein the polypeptide drug is insulin. 43. A composition as claimed in claim 36 wherein the powder formulation comprises particles of from about 2 microns to about 45 microns.

Details for Patent 5,011,678

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	10/28/1982		2039-02-26
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	12/29/2015		2039-02-26
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	08/06/1998		2039-02-26
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	03/31/1994		2039-02-26
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	05/25/2018		2039-02-26
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-02-26
Baxter Healthcare Corporation	MYXREDLIN	insulin human	Injection	208157	06/20/2019		2039-02-26